Sentences with phrase «rejuvenation biotechnology»

He currently manages the CTSCC (CASMI Translational Stem Cell Consortium) program, the Alliance program and the development of a Rejuvenation Biotechnology Translational Consortium (RBTC).

Rejuvenation biotechnology is a new platform of biomedicines that apply the principles of regenerative medicine to the structure of the body at all levels: from organs and tissues, to cells, all the way down to the molecular structures within and surrounding them.

The Denver project is designed to assess the impact not only of increased longevity per se, but also the extended years of healthy and productive life that would be expected to follow from the application of a rejuvenation biotechnology approach to the treatment of aging - related disease.

The Undoing Aging conference, a collaboration between the SENS Research Foundation and Michael Greve's Forever Healthy Foundation, took place on March 15 - 17 in Berlin, and it saw many researchers, advocates, investors, and other important members of the longevity community gather together to learn about the latest progress in rejuvenation biotechnology.

«Rejuvenation biotechnology began as a concept that few researchers understood, so our extramural research was necessarily guided by our own assessment of other researchers» suitability, rather than by researchers coming to us with proposals.

Please see the announcent from our recent Rejuvenation Biotechnology Conference here, starting at 2h15m6s:

We are happy to report that the first of our annual Rejuvenation Biotechnology Conferences — RB2014 — was a rousing success.

The Rejuvenation Biotechnology Conference series is SENS Research Foundation's current program of ground - breaking academic / industrial meetings, hosted in sunny California.

So when AFFiRiS» Schneeberger opines that «given the mode of action of disease modifiers», an AS - clearing immunotherapy such as PD01A (or PRX002) is «really something we need to apply early in this disease» because «once the the brain cells are destroyed, getting them back is probably impossible,» he is adopting a view that is entirely reasonable — but only because it is constrained to the specific plank in the integrated platform that rejuvenation biotechnology must become.

It will be one of the hardest forms of damage to repair via rejuvenation biotechnology; the only one that springs to mind as likely being even more difficult is the matter of damaged nuclear pore proteins in long - lived cells, single molecules that might be as old as you are, doing the same job for an entire human life span.

Having previously published data on a variety of experimental mAbs against AS species in animal models -LRB-[16,20]; possibly [21]-RRB-, Prothena's Dale Schenk presented new data on additional experimental antibodies at SENS Research Foundation's Rejuvenation Biotechnology 2014 conference, roughly contemporaneous to its publication, [22] along with information specific to the humanized candidate PRX002, which is now being advanced into clinical trials.

We note here an example of the perverse siloing of the various subfields of rejuvenation biotechnology that emerged during the question period that followed the surprisingly reserved delivery of the exciting news at the AFFiRiS press conference.

Beyond that, Dr. Andersen has shown in unpublished work (presented at the 2014 Rejuvenation Biotechnology Conference8) that eliminating senescent astrocytes confers similar benefits to mice with a model of PD that more closely mimics the fundamental processes that drive Parkinson's in aging people not suffering from either environmental toxicity or rare, genetic causes of PD.

«It will be one of the hardest forms of damage to repair via rejuvenation biotechnology; the only one that springs to mind as likely being even more difficult is the matter of damaged nuclear pore proteins in long - lived cells»

A Competitor Mounts the Starting Blocks It would be exciting enough for one AS - targeting rejuvenation biotechnology (or one and a half, if PD03A is counted separately) were making such progress through the clinical pipeline, especially in light of the early hints of a disease - modifying effect.

And they have a sound grounding in the data — when considering aggregate clearance as a monotherapy, in isolation from developments in other areas of rejuvenation biotechnology.

One such rejuvenation biotechnology is under development by Oisín Biotechnologies, a startup launched in 2015 with seed funding and access to intellectual property from the Foundation and our allies at the Methuselah Foundation.

Presentation at Rejuvenation Biotechnology 2014 (RB2014), August 21 - 23, 2014 Santa Clara, California.

The SENS Research Foundation has assembled a set of narrated cellular biochemistry animations that serve as an introduction to the various distinct projects that make up the field of rejuvenation biotechnology.

Although the trials are in their earliest stages, they bring the hope that this rejuvenation biotechnology will begin preventing and reversing Parkinson's disease and less specific disorders of aging soon.

As widely covered in the mainstream press, a successful proof - of - principle study for this rejuvenation biotechnology has now been performed.

(12,13) The potential for turning this animal research into a working rejuvenation biotechnology is drawing close.

In a previous post, we surveyed an exciting new development in rejuvenation biotechnology: the sudden emergence and rapid progress toward the clinic of vaccine - and antibody (Ab)- based immunotherapy to remove α - synuclein aggregates from the aging brain.

PRX002: Targeting C - Truncated Alpha - Synuclein When we last reported news from Prothena Corp PLC, their cofounder and CEO Dr. Dale Schenk had recently presented the results of studies using their AS - targeting antibodies at SENS Research Foundation's Rejuvenation Biotechnology 2014 conference.

Prospects in Competition and Cooperation The entry of these two AS - targeting rejuvenation biotechnologies into human clinical testing would seem to mark an inflection point.

But fortunately, the first such rejuvenation biotechnologies are coming on fast.

As ever, SENS Foundation is committed to making investments in critical - path research to advance this key but heretofore - neglected line of biomedical research out of the laboratory, into the clinic, and to uniting the multiple strands of rejuvenation biotechnologies into a comprehensive panel for the restoration of the health, vigor, and open futures of aging humanity.

Progress likewise proceeds apace in rejuvenation biotechnologies targeting the other key aging damage driving Parkinson's disease specifically.

Improved rejuvenation biotechnologies would target senescent cells more selectively, and SENS Research Foundation is helping to advance those next - generation «senoablatives» even as UNITY prepares for human testing.

And then one after another, rejuvenation biotechnologies that replace missing dopamine - producing cells, destroy senescent cells in the brain, and keep our mitochondrial energy centers humming will become available.

There is work to be done to advance all of these individual rejuvenation biotechnologies into and through clinical testing.

Question of the Month # 9: What is the role of novel diagnostics in rejuvenation biotechnologies?

We also encourage you to visit our Donate page if you wish to invest in the future of rejuvenation biotechnologies.

By reconstructing the structured order of the living machinery of our tissues, these rejuvenation biotechnologies will restore the normal functioning of the body's cells and essential biomolecules, returning aging tissues to health and bringing back the body's youthful vigor.

is also a gateway to the growing community of advocates, researchers, supporters, and many other people who are materially supporting progress towards the rejuvenation biotechnologies of tomorrow.

While these rejuvenation biotechnologies give us much reassurance even about the hypothetical dysfunctional mutations, someone should ask the question: where will we take these new healthy cells that we plan to use in cell therapy?